this baby is going to 17 and then 18 easy once the dust settles. with shares moving out of the founder/major owners hands into public/M-funds there will be more volatility upwards. Peter green is our hero.
They didn't do a secondary, they just sold some of what they had. When the market realizes this it will come storming right back.
OK - sounds good to me, lets move this puppy up to $45.37/share because with 44M shares outstanding that would value this at $2B. BUY IT!
See it come roaring right back.
So, for those of us lucky to get in here, it looks like a great buying opportunity. We get a huge discount and bring back some of the value to longs.
No game changer, just market manipulation. This stock doubled on nothing more than changing where it trades. It is stil a $400M market cap for a 14-person company still a DECADE away from having a drug approved.
You are dreaming. It is overpriced where it is now, just be happy it is even this high.
The NASDAQ website stock consultant says there is lots of support and no resistance, it has all cleared out as of today. Yesterday there still was some. This may be time to jump in.
What matters is progress. Clearly the efficacy supports Eteplirsen for approval, but the inept management team can't even get the application filed. The latest delay to mid-year 2015 will probably slip again on some inconsequential data element with the promise that next time will really really be it, and to ignore the last 5 delays.
I'm just curious how many more free passes investors are going to give management. SRPT has potential for sure, but needs new management to get there.
And before you bash-reply, think about it a moment - what if they slip AGAIN? How many slips are too many? 5 major delays and counting. How many is too many?
You can't undo the damage done by TheCrookedStreet. While the study was for 38-weeks all along, the outright statement by TheCrookedStreet that ISIS intentionally changed the duration in order to embellish the results has irreparably harmed shareholders of ISIS.
This isn't a journalistic opinion, it is an outright lie by Adam Feuerstein specifically designed to mislead investors and hurt shareholders. Presumably for the benefit of short sellers who tell Adam Fuerestein what to do.
This isn't about freedom of speech, this is akin to yelling FIRE in a crowded movie theater - sometimes lies cause real harm.